CN1190581A - 复方利福平注射液 - Google Patents

复方利福平注射液 Download PDF

Info

Publication number
CN1190581A
CN1190581A CN98113445A CN98113445A CN1190581A CN 1190581 A CN1190581 A CN 1190581A CN 98113445 A CN98113445 A CN 98113445A CN 98113445 A CN98113445 A CN 98113445A CN 1190581 A CN1190581 A CN 1190581A
Authority
CN
China
Prior art keywords
injection
effect
isoniazid
pyrazinamide
tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98113445A
Other languages
English (en)
Inventor
高绪侠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN98113445A priority Critical patent/CN1190581A/zh
Publication of CN1190581A publication Critical patent/CN1190581A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种用于治疗结核病的注射药物,其成分为:1000ml该药物内含利福平30～70g、异烟肼25～60g、吡嗪酰胺40～80g、丙二醇300～600ml、磷酸盐缓冲液余量。本发明具有吸收完全、作用迅速、疗效确切的特点,并且可治疗全身各器官、各种类型的结核病,用途广泛,尤其对难治、复治病例疗效显著。此外,本发明减少了毒、副作用,避免了肝脏的首过效应和胃肠道副作用,并且减少了过敏反应。

Description

复方利福平注射液
本发明涉及一种用于治疗结核病的注射药物。
利福平、异烟肼、吡嗪酰胺是常用的抗结核药物。利福平(Rifampicin)为广谱高效抗菌药，特别对结核杆菌有高度的抗菌活性，难溶于水，易溶于甲醇、醋酸乙酯。临床应用中发现，细菌对利福平极易产生耐药性，口服利福平对人体毒副作用较多，特别是对肝脏和消化道的作用。异烟肼(Isoniazid)具有特异性的抗结核杆菌作用，毒性小，但结核杆菌对该药易产生抗药性，长期服用易引起肝损害，该药对神经系统也有副作用。吡嗪酰胺(Pyrazinamide)对细胞内的结核杆菌有杀灭作用，其副作用较多，并与剂量大小有关。上述三种药中异烟肼有注射剂，利福平、吡嗪酰胺只有口服制剂，口服药无法避免其对肝脏和消化道的毒副作用，并且没有复合药物，其功效单一。
本发明的目的是提供一种主要成份为利福平、异烟肼和吡嗪酰胺的抗结核注射剂，以提高疗效，延缓细菌产生耐药性，减少药物对肝脏和消化道的毒副作用。
本发明的方案是：一种治疗结核病的复方注射剂，其成份为：1000ml注射剂内含利福平30～70g、异烟肼25～60g、吡嗪酰胺40～80g、丙二醇300～600ml、磷酸盐缓冲液余量。
上述磷酸盐缓冲液的成份为：每1000ml内含磷酸二氢钠1.8～4.2g、磷酸氢二钠3.8～8.6g、水余量。
本发明成功地将利福平、异烟肼和吡嗪酰胺组合成一种全新抗结核病注射剂药物，解决了利福平难溶于水及溶解后的稳定性问题，延缓了细菌产生耐药性。本发明具有吸收完全、作用迅速、疗效确切的特点，并且可治疗全身各器官、各种类型的结核病，用途广泛，尤其对难治、复治病例疗效显著。此外，本发明减少了毒、副作用，避免了肝脏的首过效应和胃肠道副作用，并且减少了过敏反应。
本发明的实施例如下(每1000ml注射液内含)：
Figure A9811344500031
上述磷酸盐缓冲液为：将磷酸二氢钠1.8～4.2g、磷酸氢二钠3.8～8.6g溶于注射用水1000ml中配制而成，该缓冲液的PH值应为6.0～7.5。
本发明的制备方法为：
1、将所需的磷酸盐缓冲液分成A、B两部分；
2、将异烟肼和吡嗪酰胺加入磷酸盐缓冲液A中，加热使其完全溶解，称为甲液；
3、将利福平加入丙二醇中，搅拌使其溶解，称为乙液；
4、将甲液加入到乙液中，并兑加磷酸盐缓冲液B；
5、加入活性炭，加热煮沸后放至室温；
6、过滤、灌装、消毒灭菌。

Claims (2)

1、一种用于治疗结核病的注射药物，其特征在于成份为：1000ml该药物内含利福平30～70g、异烟肼25～60g、吡嗪酰胺40～80g、丙二醇300～600ml、磷酸盐缓冲液余量。
2、按权利要求1所述的注射药物，其特征在于磷酸盐缓冲液为：1000ml该缓冲液含磷酸二氢钠1.8～4.2g、磷酸氢二钠3.8～8.6g、水余量。
CN98113445A 1998-02-25 1998-02-25 复方利福平注射液 Pending CN1190581A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98113445A CN1190581A (zh) 1998-02-25 1998-02-25 复方利福平注射液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98113445A CN1190581A (zh) 1998-02-25 1998-02-25 复方利福平注射液

Publications (1)

Publication Number Publication Date
CN1190581A true CN1190581A (zh) 1998-08-19

Family

ID=5223170

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98113445A Pending CN1190581A (zh) 1998-02-25 1998-02-25 复方利福平注射液

Country Status (1)

Country Link
CN (1) CN1190581A (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
CN100348193C (zh) * 2005-10-09 2007-11-14 沈阳双鼎制药有限公司 一种利福平药物及其制备方法
CN1989966B (zh) * 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US7094397B2 (en) 1997-08-14 2006-08-22 Vanderbilt Unversity Methods and reagents for the treatment of multiple sclerosis
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
WO2000057187A3 (en) * 1999-03-19 2001-04-19 Univ Vanderbilt Diagnosis and treatment of multiple sclerosis
CN100348193C (zh) * 2005-10-09 2007-11-14 沈阳双鼎制药有限公司 一种利福平药物及其制备方法
CN1989966B (zh) * 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物

Similar Documents

Publication Publication Date Title
CA1288346C (en) Use of n-acetylglucosamine for the therapy of degenerative joint disease and related diseases
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AP2001002288A0 (en) Methods for treatment of sickle cell anemia.
JPH0534337B2 (zh)
JP2002524415A5 (zh)
TR200103153T2 (tr) Yeni bileşimler
US11896598B2 (en) Appetite suppressant compositions and methods thereof
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
JPS63145229A (ja) ビタミンｂ６含有医薬組成物
CN1190581A (zh) 复方利福平注射液
FR2497669A1 (fr) Preparation pharmaceutique ayant d'excellentes proprietes d'absorption
JPS58131962A (ja) 新規アミノ酸誘導体の製法
WO2005065429B1 (en) Composition and method for treatment of hepatic encephalopathy
CA3074541C (en) Appetite suppressant compositions and methods thereof
CN100377712C (zh) 葫芦素脂质体组方及其制剂
KR960015953B1 (ko) 피부에 축적하는 외용의 항바이러스성 약학적 조성물 및 그 제조방법
JP3096052B2 (ja) 脂質代謝調節剤
CA2408920A1 (en) Methods for prevention of ulcers and improving physiological performance
CN102391499B (zh) 一种还原刺激下快速释放乳香酸活性成分的聚合物的制备方法
JPS632926A (ja) 安定な、注射可能な制吐性組成物
WO2005041952A1 (fr) Composition pharmaceutique possedant une activite cerebrale vasodilatatrice et nootropique
CN101690714A (zh) 一种用于抗微生物、原虫和肿瘤的大蒜素脂质体及其制备方法
CA2321265A1 (en) Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
JPS5998013A (ja) 可溶性ジメチルキサンチン誘導体の新規な経口投与しうる薬学的形態
BE903368A (nl) Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten

Legal Events

Date Code Title Description
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Gao Xuxia

Document name: Approval notice for cost mitigation

C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication